CATHERINE DIMAPILIS: Open Payments
NPI 1861179384 · INDIO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$269 in 13 payments from 8 companies in 2025. Trend: 2023 $111 · 2024 $678 · 2025 $269
Food & beverage: $269
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 3 | $66 |
| AKEBIA THERAPEUTICS INC | 3 | $59 |
| Fresenius USA Marketing, Inc. | 2 | $43 |
| Novo Nordisk Inc | 1 | $27 |
| Vifor Pharma, Inc. | 1 | $22 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| Medtronic, Inc. | 1 | $14 |
Products named: IBSRELA, Vafseo, VELPHORO, Ozempic, Veltassa, Kerendia, LOKELMA, ELLIPSYS VASCULAR ACCESS SYSTEM.
Industry payments across CA — which companies pay providers there.
